Literature DB >> 27622999

Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.

Montserrat Fraga1, Nicolas Fournier, Ekaterina Safroneeva, Valérie Pittet, Sébastien Godat, Alex Straumann, Andreas Nydegger, Stephan R Vavricka, Darius Moradpour, Alain M Schoepfer.   

Abstract

BACKGROUND AND AIM: Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation of inflammatory bowel disease (IBD). We aimed to assess the prevalence of PSC in the Swiss Inflammatory Bowel Disease Cohort Study, to identify associated risk factors, and to describe the long-term evolution. PATIENTS AND METHODS: Data of patients enrolled into the Swiss Inflammatory Bowel Disease Cohort Study were analyzed. Logistic regression modeling was performed to identify risk factors for PSC.
RESULTS: Among 2744 patients [1188 ulcerative colitis (UC); 1556 Crohn's disease (CD)], 57 had PSC (48 UC-PSC, nine CD-PSC). The prevalence of PSC was higher in UC compared with CD (4.04 vs. 0.58%, P<0.001). We identified the following significant independent risk factors for PSC in patients with UC: male sex [odds ratio (OR) 2.771, P=0.022], pancolitis (OR 2.855, P=0.011), nonsmoker at diagnosis (OR 9.253, P=0.030), and a history of appendicectomy (OR 4.114, P=0.019). During a median follow-up time of 74.8 months, four (7.0%) of PSC patients developed cholangiocarcinoma, six (10.5%) underwent liver transplantation, and five (8.8%) died. Survival of IBD-PSC patients was significantly worse compared with IBD patients without PSC (P=0.001). UC-PSC patients developed significantly more frequently colorectal cancer compared with UC patients without PSC (2/48 vs. 9/1440, P=0.017).
CONCLUSION: Approximately 4% of UC patients and 0.6% of CD patients had PSC. Male sex, pancolitis, nonsmoker status, and a history of appendicectomy were significantly associated with PSC. PSC is associated with considerable morbidity and mortality in the long term.

Entities:  

Mesh:

Year:  2017        PMID: 27622999     DOI: 10.1097/MEG.0000000000000747

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  16 in total

1.  Overview of Extraintestinal Manifestations of Inflammatory Bowel Disease.

Authors:  Millie D Long
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

Review 2.  The evolution of natural history of primary sclerosing cholangitis.

Authors:  Will R Takakura; James H Tabibian; Christopher L Bowlus
Journal:  Curr Opin Gastroenterol       Date:  2017-03       Impact factor: 3.287

3.  Risk factors and clinical courses of concomitant primary sclerosing cholangitis and ulcerative colitis: a Korean multicenter study.

Authors:  Yong Eun Park; Jae Hee Cheon; Jae Jun Park; Yoon Jae Kim; Chang Hwan Choi; Yehyun Park; Soo Jung Park; Tae Il Kim; Won Ho Kim
Journal:  Int J Colorectal Dis       Date:  2018-07-09       Impact factor: 2.571

Review 4.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 5.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 6.  Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease.

Authors:  Wendy A Goodman; Ian P Erkkila; Theresa T Pizarro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09-08       Impact factor: 46.802

7.  Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.

Authors:  James H Tabibian; Ahmad H Ali; Keith D Lindor
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

Review 8.  Cholangitis: Diagnosis, Treatment and Prognosis.

Authors:  Amir Houshang Mohammad Alizadeh
Journal:  J Clin Transl Hepatol       Date:  2017-09-07

Review 9.  Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.

Authors:  Gerhard Rogler; Abha Singh; Arthur Kavanaugh; David T Rubin
Journal:  Gastroenterology       Date:  2021-08-03       Impact factor: 22.682

10.  Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease.

Authors:  Mohamed Attauabi; Mirabella Zhao; Flemming Bendtsen; Johan Burisch
Journal:  Therap Adv Gastroenterol       Date:  2021-06-22       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.